NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

GH Research PLC (GHRS) Stock Analysis

GH Research PLC (GHRS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GHRS

$28.23

+$0.31 (+1.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GHRS with… →

GHRS Key Statistics

As of Sep 4, 2026
Trading
Open
$27.86
Previous Close
$27.92
Day's Range
27.26–28.31
52-Week Range
11.83–31.44
Volume
78.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.28
Valuation
Market Cap
$1.94B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.00
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$48.26M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
68.64M
1-Year Return
+100.93%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
283.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GHRS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+122.28%
2025+81.43%
2024+20.69%
2023−40.33%
2022−58.34%
2021 (partial year)+21.19%

As of September 4, 2026.

GHRS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$48.26M—
2024$0.00−$38.96M—
2023$0.00−$35.59M—
2022$0.00−$22.46M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$60.68M−$48.26M—
2024$0.00—−$50.25M−$38.96M—
2023$0.00—−$41.22M−$35.59M—
2022$0.00—−$30.68M−$22.46M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GHRS Valuation vs Biotechnology Median

Median of 656 stocks
MetricGHRSBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

GH Research PLC (GHRS) carries a market capitalisation of $1.94B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 73.

GHRS last closed at $28.23 on September 4, 2026. That is +$0.31 (+1.11%) against the previous close. The 52-week range on file runs from $11.83 to $31.44. The latest close sits 138.63% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $48.26M. The reported profit margin is 0%. Trailing earnings per share are −1.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.28. Daily returns over the trailing 5 years annualize to a volatility of 86.34%. Over the trailing twelve months the price has returned +100.93%. Across 5 years the annualized return works out at +5.10%.

Growth & Income

The record shows no dividend for GHRS.

The strongest complete calendar year on file is 2025 at +81.43%; the weakest is 2022 at −58.34%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +122.28% year to date.

Peer Comparison

GH Research PLC (GHRS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GH Research PLC GHRS $1.94B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. GH Research PLC has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About GH Research PLC

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Visit website →